{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-23-000054","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.258524+00:00","generated_at":"2026-06-11T13:11:29.726757+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lisata Q2 net loss $4.0M, extends cash runway to Q1 2026; tech transfer deal for TPN platform","bullets":["Net loss $4.0M in Q2 2023 vs $6.6M in Q2 2022, down 40% due to $2.2M NJ tax credit.","Cash and securities $57.6M; projected runway into Q1 2026 based on capital conservation measures.","Signed technology transfer agreement for TPN platform with Impilo Therapeutics; receives equity stake, no future capital commitment.","LSTA1 progress: ASCEND Phase 2b enrollment >70% target; BOLSTER trial open; iLSTA initiated in Australia.","FDA granted orphan designation for LSTA1 in malignant glioma; GBM trial planned for Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-23-000054","json":"https://secwatch.observer/filing/0000320017-23-000054.json","markdown":"https://secwatch.observer/filing/0000320017-23-000054.md","text":"https://secwatch.observer/filing/0000320017-23-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/0000320017-23-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/clbs-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:11:29.726757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e7c057a1543baefbb593f959d85eda1db66c3f7","claim":"LISATA THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/0000320017-23-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}